Recombinant Zoster Vaccine for High-Risk Ageing Adults in the Netherlands Cost-Effectiveness and Value of Information Analyses

Abstract

Ageing adults, especially with comorbidities are at risk of Herpes zoster (HZ) and its chronically painful complication, postherpetic neuralgia (PHN). The disease can be prevented by the Recombinant Zoster Vaccine (RZV), but a large-scale RZV program is not advisable in the Netherlands mainly due to its unfavorable cost-effectiveness. This work aims to estimate the incremental cost-effectiveness ratio (ICER) of high-risk and overall-cohort vaccination strategies compared with non-vaccination in 70-year-old Dutch people, and to prioritize future research addressing the uncertainty of the decision model.